Agios Pharmaceuticals Faces Securities Fraud Investigation Following FDA Delay of PYRUKYND Approval
核心洞察
Pomerantz LLP (搜索) is investigating Agios Pharmaceuticals for potential securities fraud following the company's announcement of a three-month FDA approval delay for PYRUKYND (mitapivat) in thalassemia treatment.
The FDA extended the PDUFA goal date for PYRUKYND's supplemental New Drug Application from September to December 7, 2025, affecting approval for alpha- or beta-thalassemia (搜索) patients.
Agios stock fell 11.03% or $4.48 per share to close at $36.13 on September 4, 2025, following the regulatory delay announcement.
Pomerantz LLP (搜索) has launched an investigation into Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) for potential securities fraud and unlawful business practices following the company's announcement of a delayed FDA approval for its thalassemia drug PYRUKYND. The investigation centers on whether company officers or directors engaged in securities violations related to the regulatory setback.
FDA Extends Review Timeline
On September 4, 2025, Agios revealed that the FDA had extended the Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) of PYRUKYND by three months to December 7, 2025. The drug, also known as mitapivat, is an oral pyruvate kinase (搜索) (PK) activator intended for treating adult patients with non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha- or beta-thalassemia (搜索).
Market Impact
The regulatory delay announcement triggered a significant market reaction, with Agios' stock price falling by $4.48 per share, representing an 11.03% decline. Shares closed at $36.13 per share on September 4, 2025, following the news.
Legal Investigation Details
Pomerantz LLP (搜索), a law firm specializing in corporate, securities, and antitrust class litigation, is urging investors who have suffered losses to come forward. The firm has a track record of recovering multimillion-dollar damages on behalf of class members in securities litigation cases.
Investors who have held shares in Agios Pharmaceuticals are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, to discuss potential participation in the investigation. The firm is seeking any information that could assist in determining whether securities fraud or other unlawful business practices occurred in connection with the FDA approval delay.